Trial Profile
A feasibility study of Pemetrexed/Bevacizumab in elderly patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms TORG1015
- 13 May 2016 Status changed from active, no longer recruiting to completed.
- 30 Apr 2012 New trial record